```html

Thrombotic Thrombocytopenic Purpura (TTP)

Overview

Thrombotic thrombocytopenic purpura (TTP) is a rare but life‑threatening blood disorder characterized by the formation of small blood clots (thrombi) in the arterioles and capillaries throughout the body. These clots consume platelets and block the flow of blood, leading to a classic pentad of symptoms:

1. Microangiopathic hemolytic anemia (MAHA)
2. Thrombocytopenia (low platelet count)
3. Neurologic abnormalities
4. Renal dysfunction
5. Fever

Although the full pentad is now recognized in < 10 % of patients, the presence of MAHA and thrombocytopenia with any organ involvement is enough to suspect TTP.

Who it affects: TTP can occur at any age, but the majority of cases are seen in adults aged 30–50. Women are slightly more affected than men (≈ 60 % vs. 40 %).

Prevalence: The incidence in the United States is about 3–4 cases per million people per year, making it an ultra‑rare disease (CDC, 2023). Prompt diagnosis and treatment have improved survival from <10 % in the 1970s to > 80 % today (Mayo Clinic, 2022).

Symptoms

Symptoms can develop rapidly over hours to days. The most common presenting features are:

• Fatigue, weakness, and pallor – due to anemia caused by red‑blood‑cell fragmentation.
• Bruising or petechiae – tiny red spots on the skin from low platelet counts.
• Bleeding gums, nosebleeds, or easy bruising – platelets are essential for clot formation.
• Neurologic changes – confusion, headache, seizures, vision disturbances, or focal deficits (e.g., weakness on one side).
• Renal signs – mild proteinuria, hematuria, or rising creatinine; severe renal failure is uncommon in classic TTP but can occur.
• Fever – low‑grade fever is frequently reported.
• Abdominal pain or nausea – caused by microvascular ischemia of the gastrointestinal tract.
• Chest pain or dyspnea – rare, but can result from myocardial ischemia from microthrombi.
• Jaundice – due to breakdown of red blood cells (hemolysis).

Because the clinical picture overlaps with other thrombotic microangiopathies (e.g., hemolytic‑uremic syndrome), laboratory tests are essential for confirmation.

Causes and Risk Factors

Pathophysiology

In > 90 % of cases, TTP is driven by an acquired deficiency of the enzyme ADAMTS13 (a disintegrin‑like and metalloprotease with thrombospondin type‑1 repeats, member 13). ADAMTS13 normally cleaves ultra‑large von Willebrand factor (UL‑vWF) multimers. When ADAMTS13 activity falls below 10 % of normal, UL‑vWF accumulates and triggers platelet aggregation in small vessels.

Two major mechanisms lead to ADAMTS13 deficiency:

1. Acquired (autoimmune) TTP – Auto‑antibodies bind and inhibit ADAMTS13. This form accounts for > 80 % of adult cases.
2. Congenital (hereditary) TTP – Mutations in the ADAMTS13 gene (known as Upshaw‑Schulman syndrome). This rare form presents in infancy or childhood but can also appear in adulthood after a trigger.

Risk Factors & Triggers

• Recent pregnancy or postpartum period (especially within the first 3 weeks).
• Use of certain medications: quinine, ticlopidine, clopidogrel, cyclosporine, and some antibiotics (e.g., vancomycin).
• Autoimmune diseases: systemic lupus erythematosus, antiphospholipid syndrome.
• Infections: HIV, COVID‑19, influenza, and certain bacterial infections.
• Malignancies: especially solid tumors and lymphomas.
• Bone‑marrow or stem‑cell transplantation.
• Genetic predisposition (familial cases of congenital TTP).

Diagnosis

A diagnosis of TTP is clinical, supported by laboratory findings. The “clinical suspicion → immediate treatment” approach is emphasized because delays increase mortality.

Key Laboratory Tests

• Complete blood count (CBC) – marked thrombocytopenia (<150 × 10⁹/L) and anemia.
• Peripheral blood smear – presence of schistocytes (fragmented RBCs), usually > 1 % of RBCs.
• Lactate dehydrogenase (LDH) – elevated due to hemolysis.
• Haptoglobin – decreased or undetectable.
• Indirect bilirubin – increased.
• Creatinine & BUN – may be mildly elevated; severe renal failure suggests other TMA.
• Coagulation profile (PT, aPTT, fibrinogen) – typically normal, helping to distinguish from disseminated intravascular coagulation (DIC).
• ADAMTS13 activity assay – definitive test; activity < 10 % confirms TTP. Turn‑around time can be 24–72 h, so treatment is started before results return.
• ADAMTS13 inhibitor testing – detects auto‑antibodies (important for distinguishing acquired from congenital).

Additional Evaluations

• Renal ultrasound or CT if renal involvement is severe.
• Neurologic imaging (CT/MRI) if stroke‑like symptoms occur.
• Pregnancy‑specific work‑up: obstetric ultrasound and fetal monitoring.

Treatment Options

Because TTP can be fatal within days, therapy must begin as soon as it is suspected.

First‑Line Therapy

1. Therapeutic plasma exchange (TPE) – Replacement of the patient’s plasma with donor plasma removes auto‑antibodies and supplies functional ADAMTS13. Standard protocol: 1–1.5 L/kg daily until platelet count & LDH normalize (usually 5–7 exchanges). (Cleveland Clinic, 2023)
2. Corticosteroids – Prednisone 1 mg/kg/day or methylprednisolone 1 g IV daily for 3 days, then taper. Reduces antibody production.

Adjunct and Refractory Therapies

• Rituximab (anti‑CD20 monoclonal antibody): 375 mg/m² weekly × 4 weeks. Useful in patients with high‑titer inhibitors, relapsing disease, or contraindications to prolonged plasma exchange.
• Caplacizumab (nanobody against vWF‑A1 domain): 10 mg IV bolus before first TPE, then 10 mg SC daily after each exchange for at least 30 days. Shortens time to platelet normalization and reduces relapse (NEJM, 2019).
• Vincristine or Cyclophosphamide** – considered in rare refractory cases.
• Recombinant ADAMTS13 (rADAMTS13) – FDA‑approved for congenital TTP (2023) and under investigation for acquired forms.

Supportive Care

• Transfusion of red cells only when symptomatic anemia or hemoglobin < 7 g/dL.
• Avoid platelet transfusions unless life‑threatening bleeding occurs.
• Manage hypertension, renal dysfunction, and seizures per standard guidelines.
• Pregnant patients: coordinate with obstetrics; TPE and steroids are safe, while caplacizumab is considered on a case‑by‑case basis.

Lifestyle & Long‑Term Management

• Vaccinations (influenza, COVID‑19, pneumococcal) – reduce infection‑related triggers.
• Hydration and a balanced diet to support kidney function.
• Medication review: avoid known precipitating drugs (quinine, ticlopidine, etc.).

Living with Thrombotic Thrombocytopenic Purpura (TTP)

Follow‑Up Schedule

• First month after remission: weekly CBC, LDH, and creatinine.
• Months 2–6: bi‑weekly labs.
• After 6 months: monthly labs for the first year, then every 3–6 months long‑term.
• ADAMTS13 activity measured every 3–6 months; a drop below 20 % predicts relapse and may prompt pre‑emptive therapy.

Daily Management Tips

1. Know your baseline – keep a copy of recent lab results and the name of your treating hematologist.
2. Monitor for early signs – new bruising, fatigue, headaches, or dark urine should prompt immediate lab checks.
3. Medication diary – record all prescription, over‑the‑counter, and herbal products; discuss new meds with your doctor.
4. Stay hydrated – aim for 2–3 L of fluid per day unless restricted for heart/kidney disease.
5. Balanced diet – include iron‑rich foods (lean meat, beans) to support red‑cell production, but avoid excessive vitamin K if on warfarin for another condition.
6. Stress management – chronic stress may influence immune dysregulation; consider mindfulness, gentle exercise, or counseling.
7. Pregnancy planning – women with a history of TTP should have pre‑conception counseling; close obstetric‑hematology collaboration is essential.

Psychosocial Support

Living with a rare, potentially recurrent disease can be stressful. Support groups (e.g., the TTP Association), mental‑health counseling, and patient‑education resources can improve quality of life.

Prevention

Because many cases are triggered by external factors, risk reduction focuses on avoidance of known precipitants and close monitoring of high‑risk individuals.

• Medication vigilance – inform every health‑care provider of your TTP history; avoid quinine, ticlopidine, clopidogrel, and certain antibiotics unless absolutely needed.
• Infection control – stay up‑to‑date with vaccinations and seek early treatment for infections.
• Autoimmune disease management – maintain optimal control of SLE, antiphospholipid syndrome, or other autoimmune conditions.
• Pregnancy monitoring – early hematology referral, regular ADAMTS13 testing, and prophylactic plasma exchange in high‑risk pregnancies.
• Lifestyle – limit alcohol excess, avoid illicit drug use (e.g., cocaine), and maintain a healthy weight.

Complications

If untreated or inadequately treated, TTP can lead to serious, sometimes irreversible complications:

• Organ infarction – brain (stroke, seizures), heart (myocardial infarction), gastrointestinal tract (ischemia, perforation).
• Renal failure – acute kidney injury requiring dialysis.
• Persistent neurologic deficits – cognitive impairment, visual loss.
• Recurrent TTP – occurs in 30‑40 % of acquired cases; each relapse carries its own mortality risk.
• Hemorrhagic complications – intracranial hemorrhage due to severe thrombocytopenia.
• Infection – from central venous catheters used for plasma exchange, or from immunosuppressive therapy.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:

• Sudden or worsening confusion, seizures, loss of consciousness, or focal neurological deficits (e.g., weakness on one side, difficulty speaking).
• Severe chest pain, shortness of breath, or palpitations.
• Rapidly increasing bruising, nosebleeds, gum bleeding, or blood in urine/stool.
• Fever > 38 °C (100.4 °F) accompanied by a drop in platelet count.
• Dark urine, jaundice, or a sudden drop in hemoglobin causing fatigue or dizziness.

These signs may indicate a life‑threatening exacerbation of TTP and require urgent plasma exchange and intensive care support.

References

• Mayo Clinic. “Thrombotic Thrombocytopenic Purpura.” Updated 2022. https://www.mayoclinic.org
• CDC. “Rare Diseases: Thrombotic Thrombocytopenic Purpura.” 2023. https://www.cdc.gov
• Cleveland Clinic. “Plasma Exchange for TTP.” 2023. https://my.clevelandclinic.org
• Joly BS, et al. “Caplacizumab treatment for acquired TTP.” NEJM. 2019;380:335‑346.
• World Health Organization. “Guidelines for the Management of Rare Blood Disorders.” 2021.
• NIH National Institute of Hematology. “ADAMTS13 and TTP.” 2022.

```